$FULC News

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

Fulcrum and Slate Medicines sign merger agreement

Fulcrum and Slate Medicines sign merger agreement

Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines

Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal

Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Slate, Fulcrum to combine in reverse merger

Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines

A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs

A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

JP Morgan Downgrades Fulcrum Therapeutics to Underweight

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3